scholarly journals Probiotics with vitamin C for the prevention of upper respiratory tract symptoms in children aged 3-10 years: randomised controlled trial

2021 ◽  
pp. 1-10
Author(s):  
I. Garaiova ◽  
Z. Paduchová ◽  
Z. Nagyová ◽  
D. Wang ◽  
D.R. Michael ◽  
...  
Keyword(s):  
Vitamin C ◽  
Respiratory Tract ◽  
Controlled Trial ◽  
Bifidobacterium Bifidum ◽  
Active Group ◽  
Controlled Study ◽  
Upper Respiratory Tract ◽  
Double Blind ◽  
Upper Respiratory ◽  
The Impact

In a double-blind, randomised, parallel-group, placebo-controlled study, healthy school children aged 3-10 years received a probiotic based supplement daily for 6 months to assess the impact on the incidence and duration of upper respiratory tract infection (URTI) symptoms. The intervention comprised Lab4 probiotic (Lactobacillus acidophilus CUL21 and CUL60, Bifidobacterium bifidum CUL20 and Bifidobacterium animalis subsp. lactis CUL34) at 12.5 billion cfu/day plus 50 mg vitamin C or a matching placebo. 171 children were included in the analysis (85 in placebo and 86 in active group). Incidence of coughing was 16% (P=0.0300) significantly lower in the children receiving the active intervention compared to the placebo. No significant differences in the incidence rate of other URTI symptoms were observed. There was significantly lower risk of experiencing five different URTI related symptoms in one day favouring the active group (Risk ratio: 0.31, 95% confidence interval: 0.12, 0.81, P=0.0163). Absenteeism from school and the use of antibiotics was also significantly reduced for those in the active group (-16%, P=0.0060 and -27%, P=0.0203, respectively). Our findings indicate that six months daily supplementation with the Lab4 probiotic and vitamin C combination reduces the incidence of coughing, absenteeism and antibiotic usage in 3 to 10 year old children.

A Placebo Controlled, Double-Blind Evaluation of Levamisole in the Reduction of the Frequency, Duration and Severity of Attacks in Children Suffering from Recurrent Upper Respiratory Tract Infections

1979 ◽  
Vol 7 (4) ◽  
pp. 302-304 ◽  
Author(s):  
F Dils
Keyword(s):  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Controlled Study ◽  
Upper Respiratory Tract ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Single Body ◽  
Upper Respiratory ◽  
Tract Infections ◽  
Adjusted Dose

In a double-blind placebo controlled study of levamisole in the treatment of children with recurrent upper respiratory tract infection (URI) eighty-six patients took part. Medication was given once a week, in a single body-weight adjusted dose. The children treated with levamisole had a statistically significantly reduced incidence of episodes of infection which were less severe, less prolonged and required less antibiotics. No side-effects were reported.

scholarly journals A study of intranasally administered interferon A (rIFN-α2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers

1988 ◽  
Vol 101 (3) ◽  
pp. 611-621 ◽  
Author(s):  
G. A Tannock ◽  
S. M Gillett ◽  
R. S Gillett ◽  
R. D Barry ◽  
M. J Hensley ◽  
...  
Keyword(s):  
Tract Infection ◽  
Respiratory Tract ◽  
Healthy Volunteers ◽  
Respiratory Tract Infection ◽  
Influenza A ◽  
Controlled Study ◽  
Response Analysis ◽  
Upper Respiratory Tract ◽  
Double Blind ◽  
Upper Respiratory

SUMMARYThe efficacy of interferon A (rIFN-α2A), an Escherichia coli-derived interferon, in the prophylaxis of acute upper respiratory tract infection, was evaluated in a community-based double-blind placebo-controlled study in the Australian winter of 1985. The trial population of 412 healthy volunteers (190 males and 222 females, aged 18–65 years) self-administered 1·5, 3·0 and 6·0 megaunits (MU) of interferon A per day or a placebo, intranasally for 28 days.The period of study coincided with an outbreak of H3N2 influenza A (detected in 35 of the 107 acute specimens) as well as substantial numbers of respiratory syncytial virus and adenovirus infections. Rhinoviruses were isolated from only three specimens. In many cases, subjects had laboratory and clinical evidence of having had more than one respiratory tract infection during the period of the study. Viruses were detected in 54 or 107 acute specimens (49%).No statistically significant differences were noted between the various treatment groups in the incidence of laboratory-proven viral infection (virus isolation and/or antibody response). Analysis of reported symptoms indicated that blood-tinged mucus and nasal stuffiness occurred more frequently with higher doses of interferon. There appeared to be no clinical benefit from the use of interferon A in the amelioration of symptoms.

scholarly journals Double Blind Controlled Study of Miroprofen in Acute Upper Respiratory Tract Infections

1982 ◽  
Vol 56 (5) ◽  
pp. 434-453 ◽  
Author(s):  
Masataka KATSU ◽  
Masakatsu HAYAKAWA ◽  
Mieko KAWAI ◽  
Ippei FUJIMORI ◽  
Michinori KOHNO ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Controlled Study ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Double Blind ◽  
Upper Respiratory ◽  
Tract Infections

scholarly journals Lacticaseibacillus rhamnosus GG DSM 33156 effects on pathogen defence in the upper respiratory tract: a randomised, double-blind, placebo-controlled paediatric trial

2021 ◽  
pp. 1-12
Author(s):  
A. Damholt ◽  
M.K. Keller ◽  
K. Baranowski ◽  
B. Brown ◽  
A. Wichmann ◽  
...  
Keyword(s):  
General Practitioner ◽  
Respiratory Tract ◽  
Controlled Trial ◽  
Oral Intake ◽  
Upper Respiratory Tract ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Upper Respiratory ◽  
Tract Infections ◽  
Cluster 2

Acute upper respiratory tract infections (URTIs) are caused by numerous viruses and bacteria. URTIs can be a cause of morbidity and are among the most common reasons for visiting healthcare practitioners and prescribing antibiotics to children in addition to causing absenteeism from school and work. Oral intake of Lacticaseibacillus rhamnosus GG DSM 33156 has shown beneficial health effects in several clinical trials, primarily relating to immune function and gastrointestinal health in children and adults. It has also been suggested that oral intake of L. rhamnosus GG DSM 33156 can reduce the incidence rate and alleviate symptoms of URTIs in children. We here report the results of a randomised, double-blind, placebo-controlled trial of 619 children aged 2-6 years conducted at a single centre in Scotland. The children, who were in day care or primary school, were followed over a 16-week intervention period with 309 randomised in the active group and 310 in the placebo group. The parents or guardians reported a daily healthcare status and any presumed episodes of URTI, which were subsequently confirmed by a general practitioner. The investigational product was well tolerated in the trial. Although a general trend towards a beneficial effect was observed, this trial did not demonstrate that L. rhamnosus GG DSM 33156 significantly reduced the incidence of URTIs, diagnosed by a general practitioner according to prespecified criteria (primary endpoint). Moreover, none of the secondary efficacy endpoints were met. Applying a Ward’s hierarchical clustering, two separate clusters, focussing on four quality of life-related endpoints, were identified. Cluster 1 was associated with more severe URTI characteristics than cluster 2. Cluster 2 was significantly enriched with children who consumed the product, indicating that the symptoms children experience during an URTI are alleviated by the intake of L. rhamnosus GG DSM 33156. The study is registered at ClinicalTrials.gov ID: NCT03636191.

Sign in / Sign up

Export Citation Format

Share Document